Financial Results | Summit Therapeutics 2025 Full Year Net Loss USD 1079.59 Million

Summit Therapeutics(SMMT) posted the Q4 of its 2025 financial results on 2/23/2026, reporting net loss of USD 1079.59 million for the year, expanding 387.81% from USD -221.32 million year over year. The EPS is USD -1.44 for the year, compare with USD -0.31 last period.

[Detailed Data]

Million USD	Q4 2025	Q3 2025	Q2 2025	Q1 2025
Total Operating Expenses	224.93	234.21	568.44	66.85
Operating Income	-224.93	-234.21	-568.44	-66.85
Net Income	-219.17	-231.79	-565.71	-62.91
Net Income Attributable to Common Shareholders	-219.17	-231.79	-565.71	-62.91
EPS(USD)	-0.2842	-0.31	-0.76	-0.09

[Company Profile]
Summit Therapeutics Inc. was incorporated in England and Wales on November 22, 2013, a Delaware corporation ("New Summit") has become the successor issuer to the company. The company is a biopharmaceutical company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The company pipeline of product candidates is designed with the goal to become the patient-friendly, new-era standard-of-care medicines, in the therapeutic area of oncology.